Summary of vaccination and host factors that can influence reactogenicity. [Image: Hervé C, et al (NPJ Vaccines 2019;4:39), CC BY 4.0]
This article looks at potential causes of vaccine reactogenicity, what influences development of symptoms, and how it can be mitigated and managed
Joan Ingram and Jennifer Andrews
References
1. Hervé C, Laupèze B, Del Giudice G, et al. The how's and what's of vaccine reactogenicity. NPJ Vaccines 2019;4:39.
2. Petousis-Harris H. Vaccine injection technique and reactogenicity--evidence for practice. Vaccine 2008;26(50):6299–304.
3. Petousis-Harris H, Poole T, Stewart J, et al. An investigation of three injections techniques in reducing local injection pain with a human papillomavirus vaccine: a randomized trial. Vaccine 2013;31(8):1157–62.
4. The Immunisation Advisory Centre. Mitigating vaccination pain and distress. 2016. https://www.immune.org.nz/resources/written-resources
5. Ministry of Health. Immunisation Handbook 2020. Wellington, NZ: Ministry of Health; 2020. https://www.health.govt.nz/publication/immunisation-handbook-2020
6. Das RR, Panigrahi I, Naik SS. The effect of prophylactic antipyretic administration on post-vaccination adverse reactions and antibody response in children: a systematic review. PLoS One 2014;9(9):e106629.
7. Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med 2020;383(27):2603–15.
8. AusVaxSafety. COVID-19 vaccine safety surveillance. 1 August 2021. https://www.ausvaxsafety.org.au/safety-data/covid-19-vaccines
